Rafael Fonseca, MD, Mayo Clinic, discusses new results from the Phase 2 GRIFFIN study of daratumumab, as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the 2021 ASH Annual Meeting.
Rafael Fonseca, MD, Mayo Clinic, discusses new results from the Phase 2 GRIFFIN study of daratumumab, as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the 2021 ASH Annual Meeting.
Rafael Fonseca, MD, Mayo Clinic,...